Cargando…

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor

No therapeutic drugs are currently available for nonalcoholic steatohepatitis (NASH) that progresses from nonalcoholic fatty liver via oxidative stress-involved pathways. Three cognate peroxisome proliferator-activated receptor (PPAR) subtypes (PPARα/δ/γ) are considered as attractive targets. Althou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamata, Shotaro, Honda, Akihiro, Ishikawa, Ryo, Akahane, Makoto, Fujita, Ayane, Kaneko, Chihiro, Miyawaki, Saeka, Habu, Yuki, Shiiyama, Yui, Uchii, Kie, Machida, Yui, Oyama, Takuji, Ishii, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451623/ https://www.ncbi.nlm.nih.gov/pubmed/37627519 http://dx.doi.org/10.3390/antiox12081523

Ejemplares similares

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
por: Tsai, Hung-Cheng, et al.
Publicado: (2019)

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
por: Møllerhøj, Mathias B., et al.
Publicado: (2022)

Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
por: van den Hoek, Anita M., et al.
Publicado: (2021)

Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography
por: Kamata, Shotaro, et al.
Publicado: (2021)

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
por: Derrett-Smith, Emma, et al.
Publicado: (2021)

Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor
por: Boeckmans, Joost, et al.
Publicado: (2019)

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
por: Haczeyni, Fahrettin, et al.
Publicado: (2017)

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
por: Hirschfield, Gideon M., et al.
Publicado: (2023)

A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death
por: Briand, François, et al.
Publicado: (2020)

Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
por: Kouno, Tetsuya, et al.
Publicado: (2022)

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates
por: Kamata, Shotaro, et al.
Publicado: (2020)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
por: Tølbøl, Kirstine S, et al.
Publicado: (2018)

The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment
por: Jena, Prasant Kumar, et al.
Publicado: (2018)

Insulin‐like growth factor‐1 signaling is responsible for cathepsin G‐induced aggregation of breast cancer MCF‐7 cells
por: Morimoto‐Kamata, Riyo, et al.
Publicado: (2017)

Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
por: Boeckmans, Joost, et al.
Publicado: (2022)

Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
por: Okazaki, Isao, et al.
Publicado: (2014)

2D DIGE proteomic analysis highlights delayed postnatal repression of α-fetoprotein expression in homocystinuria model mice
por: Kamata, Shotaro, et al.
Publicado: (2015)

Review article: vascular effects of PPARs in the context of NASH
por: Guixé‐Muntet, Sergi, et al.
Publicado: (2022)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
por: Hayashi, Momoko, et al.
Publicado: (2023)

Neutrophil Cathepsin G, but Not Elastase, Induces Aggregation of MCF-7 Mammary Carcinoma Cells by a Protease Activity-Dependent Cell-Oriented Mechanism
por: Yui, Satoru, et al.
Publicado: (2014)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Cathepsin G Induces Cell Aggregation of Human Breast Cancer MCF-7 Cells via a 2-Step Mechanism: Catalytic Site-Independent Binding to the Cell Surface and Enzymatic Activity-Dependent Induction of the Cell Aggregation
por: Morimoto-Kamata, Riyo, et al.
Publicado: (2012)

The essential John Nash
por: Nash, John, et al.
Publicado: (2002)

Molecular Pathogenesis of NASH
por: Caligiuri, Alessandra, et al.
Publicado: (2016)

Natural history of NASH
por: Armandi, Angelo, et al.
Publicado: (2021)

A Case of Psoriasis Vulgaris Treated with Brodalumab in a Hemodialysis Patient with End-Stage Renal Disease due to Diabetic Nephropathy
por: Ishibashi, Masafumi, et al.
Publicado: (2020)

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019)

Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH
por: Kanamori, Yohei, et al.
Publicado: (2021)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats
por: Ozaki, Kiyokazu, et al.
Publicado: (2018)

Stability and perfection of nash equilibria
por: Damme, Eric
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_8tjge6ehh52un1uef0s5p1uclt